Related references
Note: Only part of the references are listed.Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest
Ju-Hwa Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Anti-mitotic potential of 7-diethylamino-3(2′-benzoxazolyl)-coumarin in 5-fluorouracil-resistant human gastric cancer cell line SNU620/5-FU
Nam Hyun Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress
K. Ketola et al.
BRITISH JOURNAL OF CANCER (2012)
Lower Salinomycin Concentration Increases Apoptotic Detachment in High-Density Cancer Cells
Ju-Hwa Kim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest
Won Ki Kim et al.
INVESTIGATIONAL NEW DRUGS (2012)
Salinomycin Selectively Targets 'CD133+' Cell Subpopulations and Decreases Malignant Traits in Colorectal Cancer Lines
Tao-Tao Dong et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein
Ju-Hwa Kim et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Salinomycin inhibits osteosarcoma by targeting its tumor stem cells
Qing-Lian Tang et al.
CANCER LETTERS (2011)
Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells
Guan-Nan Zhang et al.
CANCER LETTERS (2011)
Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells
Desheng Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells
Dominik Fuchs et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines
Ju-Hwa Kim et al.
BIOCHEMICAL PHARMACOLOGY (2010)
The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor
Roberta Riccioni et al.
BLOOD CELLS MOLECULES AND DISEASES (2010)
Kitlow Stem Cells Cause Resistance to Kit/Platelet-Derived Growth Factor α Inhibitors in Murine Gastrointestinal Stromal Tumors
Michael R. Bardsley et al.
GASTROENTEROLOGY (2010)
Resveratrol Induces Growth Arrest and Apoptosis through Activation of FOXO Transcription Factors in Prostate Cancer Cells
Qinghe Chen et al.
PLOS ONE (2010)
Markers of Tumor-Initiating Cells Predict Chemoresistance in Breast Cancer
Chang Gong et al.
PLOS ONE (2010)
SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin
Ju-Hwa Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells
Dominik Fuchs et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Piyush B. Gupta et al.
CELL (2009)
Increased cytoplasmic levels of CIS, SOCS1, SOCS2, or SOCS3 are required for nuclear translocation
Kyeong-Hee Lee et al.
FEBS LETTERS (2008)
Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance
Anamaria Brozovic et al.
CANCER LETTERS (2007)
Protein kinases as drug targets in cancer
Mehmet Alper Arslan et al.
CURRENT CANCER DRUG TARGETS (2006)
Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways
Yingmei Liu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Identification of new antimalarial drugs by linear discriminant analysis and topological virtual screening
N Mahmoudi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Targeting the ERK signaling pathway in cancer therapy
M Kohno et al.
ANNALS OF MEDICINE (2006)
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks
Y Pommier et al.
ONCOGENE (2004)
Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells
R Das et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
C Knuefermann et al.
ONCOGENE (2003)
Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway
T Ohtsuka et al.
ONCOGENE (2003)
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
BL Bennett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Development of anticancer drugs targeting the MAP kinase pathway
JS Sebolt-Leopold
ONCOGENE (2000)
Share Paper
